Barclays
LEGN icon

Barclays’s Legend Biotech LEGN Stock Holding History

Barclays’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.89M Buy
195,523
+20,201
+12% +$431K ﹤0.01% 2177
2026
Q2 		$5.06M Sell
175,322
-4,578
-3% -$123K ﹤0.01% 1838
2026
Q1 		$3.25M Sell
179,900
-93,920
-34% -$1.79M ﹤0.01% 2075
2025
Q4 		$5.95M Buy
273,820
+192,748
+238% +$5.52M ﹤0.01% 2079
2025
Q3 		$2.64M Sell
81,072
-110,659
-58% -$4.09M ﹤0.01% 2672
2025
Q2 		$6.8M Sell
191,731
-42,729
-18% -$1.38M ﹤0.01% 1855
2025
Q1 		$7.96M Buy
234,460
+107,889
+85% +$3.87M ﹤0.01% 1570
2024
Q4 		$4.12M Sell
126,571
-33,779
-21% -$1.4M ﹤0.01% 2331
2024
Q3 		$7.81M Sell
160,350
-35,663
-18% -$1.9M ﹤0.01% 1670
2024
Q2 		$8.68M Sell
196,013
-10,494
-5% -$484K ﹤0.01% 1251
2024
Q1 		$11.6M Buy
206,507
+19,122
+10% +$1.15M ﹤0.01% 1285
2023
Q4 		$11.3M Sell
187,385
-93,709
-33% -$5.94M ﹤0.01% 1434
2023
Q3 		$18.9M Buy
281,094
+197,357
+236% +$13.7M 0.01% 775
2023
Q2 		$5.78M Sell
83,737
-139,801
-63% -$9.13M ﹤0.01% 1267
2023
Q1 		$10.8M Sell
223,538
-248,716
-53% -$12.2M ﹤0.01% 1127
2022
Q4 		$23.6M Buy
472,254
+171,042
+57% +$8.29M 0.01% 812
2022
Q3 		$12.3M Buy
301,212
+8,300
+3% +$390K 0.01% 791
2022
Q2 		$16.1M Buy
292,912
+47,586
+19% +$2.01M 0.01% 811
2022
Q1 		$8.92M Buy
+245,326
New +$9.7M 0.01% 955

Other funds holding LEGN

Matthews International Capital Management
Matthews International Capital Management San Francisco, California $241M AUM 42.66% 1-Year Est. Return
Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
IAMH
IvyRock Asset Management (HK) Sheung Wan, Hong Kong $190M AUM 21.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
CenterBook Partners
CenterBook Partners Greenwich, Connecticut $2.18B AUM 12.5% 1-Year Est. Return
Granite Investment Partners
Granite Investment Partners El Segundo, California $1.84B AUM 35.93% 1-Year Est. Return
Empire Life Investments
Empire Life Investments Toronto, Ontario, Canada $1.83B AUM 33.18% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Mutual of America Capital Management
Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return

Barclays's LEGN Position: Q3 2026 in Review

Barclays increased its Legend Biotech (LEGN) stake by 12% in Q3 2026, buying an estimated $431K and bringing the position to 195,523 shares worth $3.89M. The position accounts for ﹤0.01% of the portfolio, ranked #2177.

Barclays first reported a position in LEGN in Q1 2022 and has held it in 19 quarters since. The position peaked at $23.6M in Q4 2022. 75 funds tracked by Wall St. Rank hold LEGN as of Q3 2026.

  • Barclays held 195,523 shares of Legend Biotech worth $3.89M as of Q3 2026.
  • Barclays bought 20,201 Legend Biotech shares in Q3 2026, an estimated $431K.
  • Legend Biotech made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2177 holding.
  • Barclays first reported a position in Legend Biotech in Q1 2022 and has held it in 19 quarters since.
  • Barclays's Legend Biotech position peaked at $23.6M in Q4 2022.
  • 75 funds tracked by Wall St. Rank held Legend Biotech as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.